Metis TechBio Co., Ltd. Class H stock analysis
Want to see HK:7666 full AI Analyst Report?
Metis TechBio Co., Ltd. Class H (7666) Stock Price & Analysis
7666 Stock Chart & Stats
- Day’s Range
- HKD 6.87 - HKD 7.39
- 52-Week Range
- HKD 6.87 - HKD 29.98
- Previous Close
- HKD 7.29
- Volume
- N/A
- Average Volume (3M)
- 7.65M
- Market Cap
- HKD 8.62B
- Enterprise Value
- HKD 15.05B
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- ―
- Beta
- 0.38
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound
The strong 2025 revenue rebound indicates improved commercial traction and a recovery in the company’s top-line performance. If sustained, higher revenue can provide operating leverage, support investment in the business, and improve the pathway toward eventual profitability.
Gross Margin Improvement
A gross margin of roughly 66% represents a substantial improvement in product economics and suggests better mix, pricing, or cost control. Stronger gross profitability creates a more viable foundation for absorbing operating expenses and converting future revenue growth into earnings.
Balance Sheet Repair
The shift to positive equity and the dramatic reduction in debt materially strengthen financial resilience. Lower leverage reduces balance-sheet pressure and should provide greater flexibility to manage ongoing losses, allocate capital, and pursue development without the earlier debt burden.
Bears Say
Persistent Operating Losses
Despite improved revenue and gross margin, the company remains deeply loss-making at the operating and net-income levels. The scale of these losses shows that the current cost structure is not yet supported by gross profit, making a durable transition to breakeven dependent on substantial further improvement.
Continued Cash Burn
Negative operating and free cash flow means the business is not currently self-funding its operations. Continued cash consumption can require additional financing or balance-sheet resources, limiting strategic flexibility and maintaining funding risk even after the substantial reduction in debt.
Weak Shareholder Returns
Negative return on equity indicates that the repaired capital base is not yet producing adequate economic returns for shareholders. Until operating profitability improves, positive equity alone will not translate into attractive returns and may continue to weigh on the quality of capital allocation.
Metis TechBio Co., Ltd. Class H News
7666 FAQ
What was Metis TechBio Co., Ltd. Class H’s price range in the past 12 months?
What is Metis TechBio Co., Ltd. Class H’s market cap?
When is Metis TechBio Co., Ltd. Class H’s upcoming earnings report date?
How were Metis TechBio Co., Ltd. Class H’s earnings last quarter?
Is Metis TechBio Co., Ltd. Class H overvalued?
Does Metis TechBio Co., Ltd. Class H pay dividends?
What is Metis TechBio Co., Ltd. Class H’s EPS estimate?
How many shares outstanding does Metis TechBio Co., Ltd. Class H have?
What happened to Metis TechBio Co., Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Metis TechBio Co., Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
Metis TechBio Co., Ltd. Class H Stock Smart Score
Company Description
Metis TechBio Co., Ltd. Class H
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tsai-Ta Lai
- Employees
- 150
- Website
- www.metistechbio.com
- Address
- Room 201, 2/F, Building 13, Beijing, BJ, 102600, CN
Metis TechBio Co., Ltd. Class H (7666) Earnings & Revenues
7666 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 13 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 10 |










